Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study

Summary Background Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine prevents HIV infections among men who have sex with men (MSM). PrEP can be given on a daily or intermittent basis. Unfortunately, PrEP is not reimbursed in most European countries. Cost-effectiveness analyses of PrEP...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet infectious diseases 2016-12, Vol.16 (12), p.1423-1429
Hauptverfasser:	Nichols, Brooke E, Dr, Boucher, Charles A B, Prof, van der Valk, Marc, PhD, Rijnders, Bart J A, PhD, van de Vijver, David A M C, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS Anti-HIV Agents - economics Anti-HIV Agents - therapeutic use Calibration Cost analysis Cost-Benefit Analysis Disease prevention Drug dosages Emtricitabine - economics Emtricitabine - therapeutic use Epidemics FDA approval Fees & charges High income HIV HIV Infections - drug therapy HIV-1 - isolation & purification Homosexuality, Male Human immunodeficiency virus Humans Infections Infectious Disease Infectious diseases Lentivirus Male Mathematical models Mens health Models, Theoretical Mortality Netherlands Pre-Exposure Prophylaxis - methods Prevention Prophylaxis Retroviridae Sexually transmitted diseases STD Studies Tenofovir - economics Tenofovir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!